charlie51
14 Jan 2016
Re: Today's RNS What RNS? I can't see one here, nor on the company website. Can you post it?
Hardboy
14 Jan 2016
Today's RNS I can not pretend to understand the likely financial ramifications of the deal announced today; but I am assuming it is good news. If anyone can interpret it for the layman I would appreciate it.
AXA-WATCHER
30 Nov 2015
Re: Future Share price Thanks Guys for your feed back.I'm looking for something I can do as well with as Shield Diagnostics (Axis Shield) whom I invested in some years back.
Hardboy
28 Nov 2015
Re: Future Share price I agree with Charlie.It does look fully valued, but there is no reason to suspect the company will do anything but continue to grow its business slowly and profitably; and of course with small companies in profitable niche areas, there is always a strong potential for takeovers. Another you might consider - also small UK Biotech PROFITABLE business in a niche area, and limited competition because of barriers to entry is Anpario - ANP. I also like them because for a small AIM business they have a large institutional share-holding.
charlie51
28 Nov 2015
Re: Future Share price I hold. It looks pretty fully valued to me on current metrics, but the dividend policy and overall performance keeps me in (got in at £8.00). One of the other reasons I hold is that the current product set always seems to deliver on the upside - I love companies that under promise and over deliver, but also for the potential excitement highlighted in the latest finncap note which I append below
ipeline wildcards. We see a significant medium-term (FY2017E onwards) potential upside from the launch of the next-generation cardiac troponin assay, which is in the development phase and has been out-licensed to a top four diagnostics company. Revenues from this one test could easily grow to dwarf the current business. In the meantime, four new analytes have been provided to customers in the form of evaluation samples and several more are expected to be added to the catalogue portfolio during the next 18 months, delivering potential additional growth later in the decade.
AXA-WATCHER
27 Nov 2015
Future Share price What are peoples opinions on where Bioventix share price could be in say a years to 3 years time? It has been one of the shares on my watch list since the £8.00 mark, without taking the plunge, and I am looking for a company in the biotec sector to further balance my portfolio. Have I missed the boat?
charlie51
06 Nov 2015
Re: Interesting Maybe this has cleared out the only current real seller in the market? Who knows, but this is a very interesting little company.
Hardboy
06 Nov 2015
Interesting One of their biggest shareholders reduces its stake & the share price is up over a pound.
charlie51
06 Oct 2015
Re: Great Results I can only assume it's because they are not very good at cash collection. Cash is still up relative to last year so it looks good overall. In common with many smaller companies cash collection could well be an issue as they simply don't have the resources and clout to enforce payment terms as one would like to see. It's certainly something they should look at. I will ask finnCap for their view.
MrMeerkat
05 Oct 2015
Great Results Today's final results look very positive - what a great shape for a business!The only thing concerning me is why Debtors appear so large on the Balance Sheet - c176 debtor days if I do my sums right. Any thoughts?MM
MrMeerkat
23 Sep 2015
Bought Today I've been following BVXP for a few months having read Keith A-L's very positive article, and Paul Scott on Stockopedia also appears to rate them highly. Sadly I didn't buy before the results earlier in the month but have started today at 1112. While they dropped very marginally with the current market correction, I don't think they'll go lower (barring bad news) so now is as good a moment as any. Time, not timing, is a good maxim to follow anyway and I hope BVXP lives up to its reputation.MM
charlie51
16 Jun 2015
latest finnCap note says:Following the recent prelims announcement, we have fine-tuned our estimates, increasing our FY2015E and FY2016E revenue forecasts by 3% and 5%, respectively. We continue to see a mid-single digit revenue growth (translating into a double-digit EPS CAGR) for the foreseeable future, driven by positive industry forecasts (+7% pa for the global in vitro diagnostics market over the next four years), continued global rollout of vitamin D deficiency assays utilising the Bioventix's antibody and new potential product launches. We are also raising our target price from 900p to 940p.Forecast revisions. We have revised our revenue forecasts for FY2015E and FY2016E to £3.8m (from £3.7m) and £4.0 (from £3.8). Given the company’s operational gearing and its high gross margins, this translates in an increase in our adjusted EBITDA forecasts to £2.7m (from £2.6m) and £2.9 (from £2.7m), respectively. Our new EPS forecasts for FY2015E and FY2016E are 45.1p (from 43.3p) and 48.0p (from 44.9p) per share, respectively. Whilst leaving our FY2015E and FY2016E dividend forecasts unchanged, we believe there may be scope in the future to raise the dividend still further.Pipeline wildcards. We see a significant medium-term (FY2017E onwards) potential upside from the launch of the next-generation cardiac troponin assay, which is in the development phase and has been out-licensed to a top four diagnostics company. Revenues from this one test could easily grow to dwarf the current business. In the meantime, four new analytes have been provided to customers in the form of evaluation samples and several more are expected to be added to the catalogue portfolio during the next 18 months, delivering potential additional growth later in the decade.Valuation: Increased from 900p to 940p a share. Given the changes to our forecasts, we have revisited our valuation and set a new target price of 940p per share. This would place Bioventix on a P/E of 20.9x/19.6x our FY2015/16E forecasts, and still yielding 2.8%. These multiples are not out of line with other profitable diagnostic companies. We believe a premium is warranted as Bioventix’s FY2014A-16E revenue and EPS CAGRs are 6.3% and 15.3%, respectively, well above the peer group average.
zulu principle2
05 Feb 2015
interesting article [link]
moonowl
30 Nov 2014
AGM AGM on Wednesday
